Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. by Lee, Catherine J. et al.
1810 haematologica | 2017; 102(11)
Received: July 9, 2017.
Accepted: September 5, 2017.
Pre-published: September 7, 2017.
©2017 Ferrata Storti Foundation
Material published in Haematologica is covered by copyright.
All rights are reserved to the Ferrata Storti Foundation. Use of
published material is allowed under the following terms and
conditions: 
https://creativecommons.org/licenses/by-nc/4.0/legalcode. 
Copies of published material are allowed for personal or inter-
nal use. Sharing published material for non-commercial pur-
poses is subject to the following conditions: 
https://creativecommons.org/licenses/by-nc/4.0/legalcode,
sect. 3. Reproducing and sharing published material for com-













Check the online version for the most updated
information on this article, online supplements,
and information on authorship & disclosures:
www.haematologica.org/content/102/11/1810
Allogeneic blood or marrow hematopoietic cell transplantationcontinues to be the most potent anti-leukemic treatment foradult patients with standard, high-risk, or chemo-refractory
acute myeloid leukemia. Until recently, this procedure was generally
limited to those recipients who had an available matched-sibling donor
or matched-unrelated donor. Technical advances in graft cell processing
and manipulation, control of bidirectional T cell alloreactivity, graft-ver-
sus-host disease prophylaxis, and other supportive measures in hap-
loidentical transplantation now enable nearly all patients with acute
myeloid leukemia to benefit from the graft-versus-leukemia effect with
substantial reduction in procedure-related mortality. Over recent years,
haploidentical donors have been increasingly adopted as a valid donor
source in allogeneic hematopoietic cell transplantation for acute
myeloid leukemia in the absence of an HLA-matched donor. Among
centers of the European Society for Blood and Marrow Transplantation,
the use of haploidentical related donor transplantation has increased by
250% since 2010, and 291% since 2005. On behalf of the Acute
Leukemia Working Party of the European Society for Blood and
Marrow Transplantation, we summarize recent utilization trends in
haploidentical transplantation for acute myeloid leukemia and describe
the transformative changes in haploidentical hematopoietic cell trans-
plantation techniques over the past decade, which have led to the cur-
rent widespread use of this procedure. Furthermore, we review the effi-
cacy of haploidentical hematopoietic cell transplantation for acute
myeloid leukemia from available studies, including preliminary com-
parative studies, and bring attention to remaining unanswered ques-
tions and directions for future research. We conclude this report with
our recommendations for the role of haploidentical hematopoietic cell
transplantation in acute myeloid leukemia.  
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ABSTRACT
Introduction
Allogeneic hematopoietic cell transplantation (HCT) is a
potentially curative therapy for acute myeloid leukemia
(AML), with 3- to 5-year overall survival (OS) rates rang-
ing from 23% to 88%1-3 depending on the AML risk pro-
file, stage, and the presence or absence of minimal residual
disease (MRD). AML continues to be the primary indica-
tion for allogeneic HCT, and the number of these proce-
dures performed for AML among the European Society for
Blood and Marrow Transplantation (EBMT) centers has
steadily increased over the past decade, with the most
recent report showing a record number of 6,189 allogeneic
HCT performed in 2015 compared to 3,946 in 2010.4,5 In
addition to the development of reduced-intensity (RI) con-
ditioning regimens, thereby extending the use of allogene-
ic HCT for AML patients above the age of 60 or for those
with co-morbidities, the significant growth of allogeneic
HCT for AML is a result of the increased availability of
alternative donors, particularly haploidentical family
donors. 
While a HLA-matched sibling donor (MSD) remains the
preferred donor choice for optimal transplant outcomes,
in reality, approximately only 30% of patients from
Western countries have such a donor, therefore 70% of
patients require an unrelated donor source.6,7 Interestingly,
a recent analysis using population data from the USA has
challenged this well-accepted sibling match probability
and describes a variation in rates ranging between 13% to
51%.8 Perhaps more alarming is the finding of the effect of
a 40-year decline in USA birth rates on decreased availabil-
ity of a MSD for transplant-eligible patients. As such, the
current generation of young adults (18 to 44 years) will be
1.5 times less likely to find a MSD during the peak need
for HCT (at around 61 years of age) compared to their cur-
rent adult counterparts (aged 45 to 64 years).8 It is expect-
ed that a similar evolution in MSD accessibility is occur-
ring in Western Europe as total fertility rates remain low.9
These changes highlight the upcoming demand for and
utilization of alternative donor sources.
Alternative donor options include HLA-matched unre-
lated donors (MUD), partially HLA-mismatched unrelated
donors (MMUD), single or double umbilical cord blood
units (sUCB or dUCB), and haploidentical (haplo) family
donors.  While MUD have traditionally been considered
to be the next preferred donor following a MSD, the suc-
cess of finding an 8/8 HLA MUD depends on race. While
Caucasians have an approximately 75% likelihood of
finding an 8/8 MUD, the probability falls to less than 20%
for patients of African descent or other ethnic minori-
ties.7,10 Furthermore, differences in laws for donor selection
and recruitment among different countries limit or delay
the acquisition of a MUD.10 The use of an unrelated donor
or UCB product with a mismatch at one or two HLA loci
expands the accessibility of HCT to the vast majority of
patients, however, this is at the cost of an increased risk of
poor transplant outcomes and/or increased expense, par-
ticularly with the use of UCB cells. 
Over recent years, haploidentical donors have been
increasingly adopted as a valid source of donor cells for
allogeneic HCT of AML in the absence of an HLA-
matched donor.4,11 A haploidentical related donor is
defined by the sharing of one haplotype (or a single iden-
tical copy of chromosome 6) with the patient containing
the HLA region involving class I and class II histocompat-
ibility genes. However, a haploidentical family donor may
be greater than half-matched and have common alleles on
the unshared haplotype (mismatched related donor). The
most recent EBMT activity survey report described hap-
loidentical donors as a family member with two or more
loci mismatch within the loci HLA-A, -B, -C, -DRB1 and-
DQB1.4 Among centers of the EBMT, the use of hap-
loidentical transplantation (haploHCT) for malignant and
non-malignant disorders has surged by 250% since the
year 2010, and by 291% since 2005. In 2010, 802
haploHCT were performed, and this number increased to
1,571 in 2013, followed by 2,012 haploHCT in 2015.4,11
The highest utilization for haploHCT in 2015 was seen in
myeloid malignancies (n=1,008), and the majority of these
patients had a diagnosis of AML (n=735), with an equal
proportion of patients in first complete remission (CR1) or
more advanced disease (Figure 1). In contrast, the utiliza-
tion of unrelated umbilical cord blood transplantation
(UCBT) has sharply declined for myeloid and lymphoid
malignancies.4 This apparent preference for haploidentical
donors is a result of improvements in conditioning regi-
mens combined with new strategies to diminish the risk
of graft-versus-host disease (GvHD) associated with one
haplotype mismatched donors that have resulted in favor-
able clinical outcomes comparable to HLA-matched allo-
geneic HCT, compounded with the nearly universal and
immediate availability of the donor and ease of recurrent
stem cell collections for repeat cellular infusions. The abil-
ity to have rapid access to a haploidentical donor is a cru-
cial benefit for patients with high-risk AML, as a delay in
transplantation due to donor issues can result in poor out-
comes. 
On behalf of the Acute Leukemia Working Party
(ALWP) of the EBMT, herein we aim to first describe the
early strategies used in haploidentical transplantation and
the pivotal developments that have made its use universal
and available to nearly all patients requiring hematopoiet-
ic cell transplantation. We then summarize the evidence
from available studies, evaluating its efficacy in AML,
including preliminary non-comparative and comparative
studies of haploHCT with other alternative donor trans-
plants, and lastly, discuss future directions for research.
Early experiences in haploidentical 
transplantation
Initial experiences with unmodified bone marrow (BM)
haploidentical HCT in acute leukemias generated poor
outcomes as a consequence of intense bi-directional T cell
alloreactivity associated with HLA-mismatches. Limited
success was primarily related to delayed engraftment, graft
failure, and acute graft-versus-host disease (aGvHD).12-15 In
order to overcome these challenges, several alternative
strategies were developed. In 1993, investigators from the
University of Perugia pioneered a strategy of T cell-deple-
tion (TCD) with ex vivo CD34+ cell selection and in vivo
antithymocyte globulins (ATG) administration as sole pro-
phylaxis for GvHD, accompanied by infusion of a large
number of CD34+ cells following intensive myeloablative
and immunosuppressive conditioning, with the rationale
that this strategy would help promote engraftment and
decrease graft failure (Figure 2A). “Mega-doses” of stem
cells were obtained by combining TCD BM with granulo-
cyte colony-stimulating factor (G-CSF) mobilized peripher-
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al blood stem cells (PBSC).16-18 With additional modifica-
tions, 95% of patients with acute leukemia (AL) achieved
primary engraftment, and aGvHD and chronic GvHD
(cGvHD) were minimal. With more than 15 years of fol-
low-up, the relapse incidence (RI) was 17% in patients
with AML who were transplanted in any complete remis-
sion (CR), while the 17-year disease-free survival (DFS)
rate was 43%.19,20 In addition to a highly myeloablative reg-
imen, the emergence of natural killer (NK) cell alloreactions
following transplantation may explain the decreased inci-
dence of relapse and improved survival.21-24 Despite the suc-
cess of the anti-leukemic effects of this strategy, TCD
haploHCT was associated with high transplant-related
mortality (TRM) of up to 40% mainly due to a delay in
immune recovery and life-threatening infections.18,19
Findings from an EBMT retrospective analysis of 173
adults with de novo AL who received a TCD haploidentical
HCT in Europe showed similar outcomes, including high
engraftment rate, negligible GvHD, and high TRM.25 To
circumvent the pitfalls associated with TCD haploHCT,
other forms of T-cell cellular therapy were exploited,
including selective T-cell-depletion,26,27 adoptive transfer of
donor T cells following transplant,28 selective T-cell add-
backs29-32 and gene-modified donor T cells.33
Post-transplant cyclophosphamide: a pivotal
point in haploidentical transplantation
The rationale behind the use of post-transplantation
cyclophosphamide (PTCy) stems from early preclinical
studies demonstrating its role in targeting alloreactive T
cells and reducing GvHD when given within a narrow
window following allografting.34-39 Furthermore, the find-
ing of preserved hematopoietic stem and progenitor cells
(and in later work, regulatory T cells40) when exposed to
cyclophosphamide owing to the high expression of alde-
hyde dehydrogenase,41,42 gave rise to the first-in-human
clinical trial at Johns Hopkins Hospital in 1999. Thirteen
patients with high-risk hematologic malignancies under-
went T cell-replete (TCR) haploidentical bone marrow
transplantation (haploBMT) using a non-myeloablative
(NMA) conditioning regimen consisting of fludarabine
and low-dose total body irradiation (TBI), as well as 50
mg/kg of cyclophosphamide on day + 3 post-transplant,
followed by tacrolimus and mycophenolic mofetil (MMF)
on day + 4 for GvHD prophylaxis. Owing to a high rate of
graft rejection (2 out of the first 3 patients), cyclophos-
phamide 14.5 mg/kg was introduced into the conditioning
regimen. This adaptation resulted in an 80% primary
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Figure 1. Trends in haploidentical HCT in Europe between 1990-2015. (A) Increasing use to haploidentical family HCT from cord blood HCT. (B) Increasing use of
haploidentical HCT by main disease group. (C) Similar increase in rates of haploidentical HCT for AML early disease and AML advanced disease. (D) Haploidentical
HCT by cell source; bone marrow (BM) versus peripheral blood (PB). Adapted from Passweg et al.4 used under theCreative Commons License. AML: acute myeloid
leukemia;  HSCT: hematopoietic stem cell transplantation; NMD: non-malignant disorders.
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engraftment rate (8 out of 10 patients), giving proof of
concept to move into next phase studies.43
As the initial phase I study ultimately had a high cumu-
lative incidence of graft failure and severe GvHD at 6
months post-transplant, Luznik et al.44 modified the regi-
men by adding an additional dose of cyclophosphamide
50mg/kg on day + 4 post-transplant (Figure 2B). In a col-
laborative phase 2 trial between Hopkins and Seattle, 68
patients with AML (n= 27) received the revised regimen,
and results yielded an 87% engraftment rate, one-year
non-relapse mortality (NRM) and relapse of 15% and
51%, respectively, and two-year OS and event-free sur-
vival (EFS) of 36% and 26%, respectively. Additionally,
the cumulative incidences (CI) of grades II-IV and grade
III-IV aGvHD by day 200 were 34% and 6%, respectively.
A trend towards a lower incidence of extensive cGvHD
with the use of 2 doses of PTCy as compared to one dose
was noted (5% vs. 25%, P=0.05). In an updated analysis of
210 recipients of NMA haploBMT, the Hopkins group
reported similar outcomes.45
Due to the early reports of success with unmanipulated
haploidentical HCT and pioneering of PTCy for preven-
tion of GvHD, other centers, mainly in Western Europe
and the USA, have favored the use of TCR grafts over
TCD haploHCT.10,46,47 Ciurea et al.46 reported significantly
improved 1-year NRM (16% vs. 42%, P=0.02), OS (64%
vs. 30%, P=0.02) and progression-free survival (PFS) (50%
vs. 21%, P=0.02) in 65 consecutive patients treated with a
myeloablative TCR haploBMT with PTCy (n=32), com-
pared to a TCD PBSC graft with ATG followed by infu-
sion of CD34+ selected cells and no other post-transplan-
tation immunosuppression (n=33). Engraftment rate and
grade II-IV aGvHD were not significantly different,
whereas cGvHD was significantly lower in patients treat-
ed with a TCR graft. In conclusion, given the ease of
donor acquisition and administration of PTCy-based pro-
tocols alongside the favorable results seen in patients
with high-risk hematologic malignancies, more investiga-
tion into the role of haploHCT in the early steps of deci-
sional algorithms for the treatment of acute leukemias is
ongoing.
Comparative donor studies of haploidentical
transplantion for acute myeloid leukemia
Haploidentical versus matched sibling or unrelated
donor transplantation 
At present there are no prospective randomized com-
parisons of transplantations using a haploidentical donor
versus a MSD or MUD for AML. Based on several non-ran-
domized comparative studies evaluating transplantation
outcomes following haploidentical transplantation with
post-transplant cyclophosphamide or other in vivo T cell-
depletion methods,10,48-57 the combined data suggest similar
outcomes for haploHCT compared with MSD and MUD
HCT. Table 1 summarizes the available comparative stud-
ies of haploHCT with PTCy platform versus MSD or
MUD HCT. In one of the earliest studies of haploHCT
with PTCy, Bashey et al.49 demonstrated equivalent pri-
mary outcomes of 271 patients with a variety of hemato-
logic malignancies (~ 34% AML), who contemporaneous-
ly underwent a T cell-replete haploidentical MSD or MUD
transplant. However, post-relapse survival at 12 months
was unexpectedly lower compared to a well-matched
MSD or MUD HCT (17% vs. 67% vs. 63%, P<0.001). In
an updated cohort of 475 patients (~ 36% AML) and
median follow-up of 45 months, these investigators again
reported non-significant differences between haplo, MSD,
and MUD transplants in DFS (54% vs. 56% vs. 50%), OS
(57% vs. 72% vs. 59%), CI of NRM (17% vs. 14% vs.
16%), and relapse (29% vs. 30% vs. 34%) at 2 years after
transplantation. The CIs of grade II-IV aGvHD were not
significantly different between haplo and MUD HCT,
however, haploHCT was associated with a significantly
higher incidence of aGvHD compared to MSD (P=0.005
for grade II-IV). The 2-year CI of moderate-severe cGvHD
was also significantly lower in haploHCT than in MSD or
MUD HCT recipients (31% vs. 44% vs. 47%, P=<0.05),
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Figure 2. Commonly used platforms used in haploidentical-related transplanta-
tion.111 (A) University of Perugia: myeloablative conditioning and T cell-depletion
with “megadose” CD34+ cell allografts. (B) Johns Hopkins: non-myeloablative
conditioning with high-dose, post-transplantation cyclophosphamide. (C) Peking
University: myeloablative conditioning and in vivo T cell modulation (GIAC proto-
col). Panel B was adapted from Luznik et al.44 used under the Creative Commons
License. Ara-C: cytarabine; ATG: anti-thymocyte globulin; BM: bone marrow; Bu:
busulfan; CSA: ciclosporin-A; Cy: cyclophosphamide; Flu: fludarabine; GCSF:
granulocyte colony-stimulating factor; M-CCNU: semustine; MMF: mycopheno-





and showed a similar trend for patients receiving a PBSC
graft only.50 In another contemporaneously treated cohort
of 227 patients with AML/myelodysplastic syndrome
(MDS), Di Stasi et al.51 reported superimposable survival
curves between haplo and 10/10 HLA MUD HCT, a non-
significant improvement in outcomes with MSD HCT and
a similar CI of GvHD across all donor groups. 
In the largest study carried out in the USA focusing on
AML, Ciurea et al.48 utilized the Center for International
Blood and Marrow Transplant Research (CIBMTR) reg-
istry data and reported comparable 3-year OS following
haploidentical (n=192) and 8/8 HLA matched MUD HCT
(n=1982) in patients with AML in various disease stages
(CR1, CR2, and more advanced) who received either a
myeloablative (MA) (45% vs. 50%, P=0.38) or RI (46% vs.
44%, P=0.71) conditioning regimen. Further subset analy-
sis revealed no differences in 3-year NRM (14% vs. 20%,
P=0.14) or relapse (44% vs. 39%, P=0.37) by donor type in
the MA cohort, however, there was a significant decrease
in 3-year NRM (9% vs. 23%, P=0.0001) and increase in
relapse (58% vs. 42%, P=0.006) in the RI group. In both
cohorts, 3-month grade II-IV and grade III-IV aGvHD, and
3-year cGvHD were lower after haploidentical compared
with MUD transplants (MA: grade II-IV aGvHD: 16% vs.
33%, P<0.0001; grade III-IV aGvHD: 7% vs. 13%, P=0.02;
cGvHD: 30% vs. 53%, P<0.0001; RI: grade II-IV aGvHD:
19% vs. 28%, P=0.05; grade III-IV aGvHD: 2% vs. 11%,
P<0.0001; cGvHD: 33% vs. 52%, P=0.002). In this study,
the majority of recipients of haploHCT received a BM
graft, whereas PBSC were predominantly utilized in MUD
HCT. Owing to the limitations inherent in an observation-
al registry study, the investigators could not assess the
impact of the donor source of stem cells on clinical out-
comes. To address this question, Rashidi et al.52 reported
results from a single-center retrospective analysis of 140
patients who underwent a haploHCT (n=52) or MUD
HCT (n=88) with PBSC. This group showed a significant-
ly faster neutrophil and platelet recovery in the MUD
Table 1. Comparative studies of haploidentical HCT with PTCy versus matched donor HCT.
Author                  Disease,      Condition           Graft           Donor        Engraft     aGvHD           aGvHD            cGvHD                OS                DFS            Relapse          NRM
                            no of pts.   Intensity (%)    Source (%)     Type (%)          (%)       II-IV (d)         III-IV (d)            (year)              (year)            (year)            (year)           (year)
                             (AML %)                                     
Bashey et al.49           All, 271           MA (50)           BM (17)      Haplo (20)           98       30% (d180)    11% (d180)           4% (2)              64% (2)           60% (2)           33% (2)          7% (2)
                                        (34)              RI (50)             PB (83)
                                                                                       Both (<1)     MSD (43)          97.5            27%                   8%                     11%                    76%                  53%                  34%                13%
                                                                                                                                                            (P=NS)           (P=NS)           (P=0.062)           (P=NS)           (P=NS)           (P=NS)         (P=NS)
                                                                                                                MUD (37)            98             39%                  11%                    12%                     67%                  52%                  34%                16% 
                                                                                                                                                            (P=NS)           (P=NS)           (P<0.05)           (P=NS)           (P=NS)           (P=NS)         (P=NS)
Di Stasi et al. 51   AML/MDS, 227         RI                 BM (37)      Haplo (14)           97       29% (d100)      0% (d100)           11% (3)             66% (3)           30% (3)           33% (1)         24% (1)
                                        (85)                                         PB (63)
                                                                                                                MSD (38)            99             31%                  11%                    31%                    56%a                             36%                  28%                 20%
                                                                                                                                                                                                                                            (P=0.646)
                                                                                                                MUD (48)            96             29%                   6%                     21%                                               27%                  23%                 35%
                                                                                                                                                          (P=0.709)       (P=0.044)         (P=0.125)                                    (P=0.12)         (P=0.75)      (P=0.099)
Ciurea et al.48         AML, 1349             MA                BM (23)       Haplo (8)            90        16% (d90)        7% (d90)            30% (3)               45 (3)                 NR                44% (3)         14% (3)
                                       (100)                                        PB (77)        MUD (92)            97             33%                  13%                    53%                      50                                              39%                 20%
                                                                                                                                                         (P <0.0001)      (P=0.02)         (P<0.0001)         (P=0.38)                                   (P=0.37)       (P=0.14)
Ciurea et al.48                AML, 825               RI                 BM (19)      Haplo (11)           93        19% (d90)        2% (d90)            34% (3)               46 (3)                 NR                58% (3)          9% (3)
                                      (100)                                        PB (81)        MUD (89)            96             28%                  11%                    52%                      44                                              42%                 23%
                                                                                                                                                           (P =0.05)      (P<0.0001)        (P=0.002)          (P=0.71)                                  (P=0.006)    (P=0.0001)
Bashey et al.50           All, 475           MA (49)           BM (21)      Haplo (24)           97       41% (d180)    17% (d180)          31% (2)             57% (2)           54% (2)           29% (2)         17% (2)
                                        (36)              RI (51)             PB (79)                 
                                                                                                                MSD (38)            98             21%                   9%                     44%                     72%                  56%                  30%                 14%
                                                                                                                                                          (P=0.005)       (P=0.054)         (P=0.032)          (P=0.02)          (P=NS)           (P=NS)         (P=NS)
                                                                                                                MUD (38)            98             48%                  18%                    47%                     59%                  50%                  34%                 16%
                                                                                                                                                            (P=NS)           (P=NS)           (P=0.004)           (P=NS)           (P=NS)           (P=NS)         (P=NS)
Rashidi et al.52         AML, 140         MA (44)           PB (100)      Haplo (37)          100     40% (d180)    25% (d180)        10% (1.5)            42 (1.5)                NR              29% (1.5)      27% (1.5)
                                                               RI (56)                                   MUD (63)            90             36%                  25%                     9%                       37                                              43%                 27%
                                                                                                                                                           (P=0.51)         (P=0.79)           (P=0.91)           (P=0.17)                                   (P=0.08)       (P=0.54)
How et al.53               AML, 99          MA (72)           BM (99)      Haplo (24)           83       58% (d100)    28% (d100)          10% (1)             36% (2)                NR                33% (1)         26% (2)
                                                               RI (28)              PB (1)         MSD (32)            91             36%                  23%                    10%                     28%                                            28%                 42%
                                                                                                                 UD (43)b                     91              57%                  30%                    15%                     29%                                            48%                 29%
                                                                                                                                                           (P=0.11)         (P=0.74)           (P=0.61)           (P=0.75)                                   (P=0.40)       (P=0.49)
Rashidi et al.55          AML, 83          MA (42)           PB (100)      Haplo (75)           87       40% (d180)            NR                   6% (1)              53% (1)                NR                31% (1)         22% (1)
                                                               RI (58)                                    MD (25)c            100            19%                                               5%                      58%                                            26%                 16%
                                                                                                                                                           (P=0.07)                                     (P=0.86)           (P=0.31)                                   (P=0.70)       (P=0.30)
aRepresents combined MSD and MUD transplant group. bRepresents MUD (n=35), partially mismatched (n=6); mismatched (n=2). cRepresents combined MSD and MUD transplant group. aGvHD, acute graft-versus-host disease; AML: acute
myeloid leukemia; BM: bone marrow; cGvHD: chronic graft-versus-host-disease; d: day; DFS: disease-free survival; haplo: haploidentical; MA: myeloablative; MD: matched donor; MDS: myelodysplastic syndrome; MSD: matched sibling donor; MUD:
matched unrelated donor; NRM: non-relapse mortality; NR: not reported; NS: not significant; OS: overall survival; PB: peripheral blood; RI: reduced-intensity; UD: unrelated donor; yr: year.
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group, but no statistically significant difference in OS,
NRM, aGvHD or cGvHD at 1.5 years. Lastly, the refined
disease risk index (DRI) developed by Armand and col-
leagues58,59 in order to help stratify outcomes based upon
disease risk and stage has been used to compare the
effects of the graft-versus-tumor response mediated by
NMA haploBMT with PTCy against historical outcomes
in the setting of HLA-matched donor HCT following RI
conditioning.60 Risk-stratified disease and their associated
survival outcomes appeared similar between the two
groups. For example, 3-year PFS estimates in the low-,
intermediate-, and high/very high-risk patient groups fol-
lowing NMA haploBMT with PTCy were 65%, 37%, and
22%, respectively, and 66%, 31%, and 15% in the original
DRI study cohort of recipients of RI HLA-matched donor
transplantation.60
The viability of T cell-replete haploidentical HCT with
post-transplantation cyclophosphamide in patients with
active AML has also been described. How et al.53 com-
pared outcomes of 99 patients who received either a MSD
(n=32), unrelated donor (all unrelated, n=43; MUD, n=35),
or a haploidentical related (n=24) donor transplantation
for active AML, defined by ≥5% blasts in the pre-trans-
plantation BM, persistent cytogenetics, or extramedullary
disease. With a median follow-up of 18 months, no statis-
tically significant differences between MSD, unrelated
donor, and haploidentical donor HCT in 1- and 2-year OS
were identified (1 yr: 28% vs. 41% vs. 45%; 2 yr: 28% vs.
29% vs. 36%, P=0.75), EFS (1 yr: 27% vs. 28% vs. 39%; 2
yr: 18% vs. 22% vs. 23%, P=0.93), TRM (1 yr: 42% vs.
23% vs. 26%; 2 yr: 42% vs. 29% vs. 26%, P=0.49), or 1-
year relapse (28% vs. 48% vs. 33%, P=0.40). Similarly, the
CI of grades III-IV aGvHD at day 100 (23% vs. 30% vs.
28%, P=0.74) and severe cGvHD at 1 year (10% vs. 15%
vs. 10%, P=0.61) were comparable. Although not evaluat-
ed in a comparative donor study, RI T cell-replete
haploHCT incorporating donor change and utilizing PTCy
for postgrafting immunosuppression has also been suc-
cessfully used for patients with AL relapsing after a first
autologous or allogeneic transplantation.61 These results
preliminarily support the decision to use a haploidentical
related donor source in transplantation of patients with
active AML or relapsed AML after first transplantation, as
both of these patient populations have an urgent indica-
tion to proceed to transplantation and may have a readily
available haploidentical family donor.
The ALWP of the EBMT have also published results of
several large multi-center comparative studies using
EBMT registry data (Table 2). In the first retrospective
comparative analysis of 10,679 patients with AL who
received allogeneic HCT from a MSD or a haploidentical
donor, Ringden et al.62 sought to determine whether a
stronger graft-versus-leukemia (GvL) effect is exerted with
T cell-deplete or T cell-replete haploidentical transplanta-
tion due to the presence of mismatched major HLA anti-
gens on leukemic cells. The investigators determined no
difference in the probability of relapse between recipients
of haploidentical and MSD grafts. In a more recent study,
Salvatore et al.56 compared outcomes of T cell-replete
haploHCT (n=185) to those from MSD HCT (n=2,469)
among 2,654 adults with intermediate-/high-risk AML in
first CR. GvHD prophylaxis consisted of PTCy in 74% of
patients and ATG in 26%. In multivariate analyses of
patients with intermediate-risk AML, haploHCT was
associated with reduced 2-year leukemia-free survival
(LFS), OS and GvHD-free, relapse-free survival (GRFS),
and higher NRM as compared to MSD HCT. In high-risk
AML patients, 2-year RI was lower in haploHCT, howev-
er, no other differences were observed in NRM, LFS, OS,
and GRFS.56 In a separate registry study which focused on
6,545 patients with poor-risk AML in CR1, Versluis et al.57
reported similar 2-year OS following MSD (n=3,511) with
10/10 MUD (n=1,959) and haploHCT (n=193) (hazard
ratio [HR], 0.99 and 1.12, respectively), whereas both 9/10
MUD (n =549) and UCB (n=333) grafts were associated
with inferior OS (HR, 1.23, P=0.005; and HR, 1.54,
P<0.001, respectively). Although the RI was decreased for
10/10 MUD (HR, 0.74, P<0.001) and haplo (HR, 0.60,
P=0.001) compared with MSD HCT, NRM was signifi-
cantly higher. Lastly, Piemontese et al.54 described clinical
outcomes from T cell-replete haploHCT versus allogeneic
transplants from 10/10 HLA matched and 9/10 HLA mis-
matched unrelated donors (MMUD) for adult patients
with de novo AL in CR1/CR2. In this cohort, 265 patients
(AML, n=176) received a haploHCT, 2,490 patients (AML,
n=1,645) received a 10/10 MUD, and 813 patients (AML,
n=510) received a MMUD transplant. Post-transplant
cyclophosphamide was used as GvHD prophylaxis in
40% of haploHCT. Among patients with AML, 3-year
LFS, OS, and NRM were significantly improved in 10/10
MUD compared to haploHCT, but there was no differ-
ence in GRFS, grade II-IV aGvHD or cGvHD. Further, no
differences were found in GvHD or survival outcomes
between 9/10 MMUD HCT and haploHCT. Based on the
collective data, outcomes from haploidentical transplanta-
tion are encouraging, however, a larger cohort, longer fol-
low-up period, and prospective comparative donor analy-
ses are needed in order to firmly establish its place in the
hierarchy of alternative donors. At this time, the ALWP-
EBMT supports a 10/10 MUD as the best donor option in
the absence of a MSD, and further supports the use of a
haploidentical donor or 9/10 MMUD as equally viable
alternatives in the absence of a fully matched donor, or in
the case of the need for an urgent transplant. 
Haploidentical versus UCBT
Single- and multi-center studies have also shown the
value of single or double UCBT for AML in the setting of
an urgent need for transplant and lack of an HLA-matched
sibling or an unacceptable unrelated donor.63-68 Therefore,
early comparative studies of alternative donor sources
focused on examining differences in clinical outcomes
with the use of haploidentical or UCB as sources of stem
cells (Figure 3).65,69-72 In the earliest retrospective compara-
tive study, the Eurocord group, in collaboration with the
ALWP-EBMT, reported outcomes on 220 adult recipients
who received T cell-deplete haploHCT with PBSC
(n=154) or unrelated single or double UCBT (n=66) for
AML. The 2-year incidences of relapse, TRM and LFS
were not statistically different after haploHCT or UCBT,
however, UCBT was associated with delayed neutrophil
recovery and a higher incidence of aGvHD.69 In another
large EBMT observational study of 918 AML patients
(haplo, n=158; UCBT, n=558), Ruggeri et al.71 demonstrat-
ed similar findings of a comparable RI (HR=0.95, P=0.76),
NRM (HR=1.16, P=0.47), and LFS (HR=0.78, P=0.78)
between unmanipulated haploHCT and UCBT. While
grade II-IV and grade III-IV aGvHD were similar between
the two groups, the CI of cGvHD was less in the UCBT
cohort (HR=0.63, P=0.008). 
Haploidentical HCT in AML 
haematologica | 2017; 102(11) 1815
In order to study the reproducibility of the results found
in retrospective analyses, the USA Blood and Marrow
Transplantation Clinical Trials Network (BMT CTN) con-
ducted two parallel multicenter prospective clinical trials
focused on outcomes associated with unmanipulated relat-
ed haplo-BM graft with PTCy (n=50) and dUCBT (n=50)
Table 2. Published ALWP-EBMT studies of haploidentical transplantation in adults with AML.
Reference (year)                            Study Objective                                                                                 Conclusions
Rocha et al.69 (2005)                            Retrospective comparative analysis of outcomes of 364 adult               In AML, no difference between groups in relapse, TRM, and LFS. 
                                                                  patients with AML/ALL receiving either UCBT versus                                UCBT had increased grade II-IV aGvHD.
                                                                  T cell-depleted PB haploHCT between 1998-2002.
Ciceri et al.25 (2008)                             Retrospective analysis of outcomes of 266 adult patients with              Engraftment occurred in 91% of the patents; 2-year LFS was 
                                                                  de novo acute AML/ALL receiving T cell-depleted PB                               48% ± 10% for patients with AML in CR1; 21% ± 5% in ≥ CR2; and 
                                                                  haploHCT between 1995-2004.                                                                         1% ± 1% in non-remission; GvHD was minimal.
Gorin et al.110 (2015)                            Matched pair analysis of outcomes of 188 T cell-replete                        Haploidentical centers were divided into “expert” vs. “regular” 
                                                                  haploHCT and 356 autologous transplants (ASCT) in adult                     based on the number of haploHCT performed. NRM was higher 
                                                                  patients with acute leukemia between 2007-2012.                                      among all haploHCT compared to ASCT. LFS and OS were higher 
                                                                                                                                                                                                   following ASCT compared to haploHCT in regular centers and similar 
Ruggeri et al.71 (2015)                         Retrospective comparative analysis of outcomes of 1,446 adult            In multivariate analysis of the AML group, UCBT was associated with 
                                                                  patients with de novo AML/ALL receiving either UCBT versus                lower cGvHD. No significant differences in relapse, NRM, and LFS
                                                                  unmanipulated haploHCT between 2007-2012.                                            between the two groups. 
Piemontese et al.10 (2015)               Retrospective analysis of outcomes of 229 adult patients with              Engraftment occurred in 93% of the patents; For the total group:  
                                                                  de novo AML/ALL in CR or non-remission who received                         3-year relapse, LFS, OS and NRM was 42%, 30%, 37%, and 28%.
                                                                  an unmanipulated haploHCT between 2007-2011.                                       100-day CI of Grade II-IV aGvHD (32%) and 3-year CI of 
                                                                                                                                                                                                   cGvHD (34%) were similar to historical outcomes of MSD HCT. 
Ringden et al.62 (2016)                        Retrospective comparative analysis of relapse and survival                   No difference in relapse between MSD and haploHCT groups 
                                                                  outcomes of 10,679 adult patients with AML/ALL receiving                     while NRM and LFS was superior in the MSD group.
                                                                  MSD HCT versus T cell-replete or deplete haploHCT 
                                                                  between 2007-2012.
Rubio et al.88 (2016)                             Retrospective comparative analysis of outcomes of 696 adult               Multivariable analysis in AML showed no difference in NRM, cGvHD, 
                                                                  patients with AML/ALL receiving T cell-replete haploHCT with RI        LFS, and OS. There was a trend toward high relapse with RI 
                                                                  versusMA conditioning regimen between 2001-2012.                                conditioning.
Sun et al.82 (2016)                                Retrospective one-to-one matched pair comparative study of              Similar 5-year LFS, OS, relapse, NRM, grade III-IV aGvHD, 
                                                                  outcomes following GIAC-based haploHCT and MA 10/10 MUD             and cGvHD.
                                                                  HCT in 174 patients with de novo intermediate-risk 
                                                                  (based on cytogenetics) AML in CR1.
Ruggeri et al.89 (2016)                         Retrospective comparative analysis of outcomes of 451 adult               Multivariable analysis showed that PB was associated with increased 
                                                                  patients with AML/ALL in CR1/CR2 receiving T cell-replete                    risk of grade II-IV aGvHD. Otherwise, no significant difference in 
                                                                  haploHCT with PTCy with PB versus BM stem cells                                   other GvHD or survival outcomes.
                                                                  between 2010-2014.                                                                                             
Piemontese et al.54 (2017)                 Retrospective comparative analysis of outcomes of 3,568 adult            Weighted Cox model showed significantly higher LFS and OS
                                                                  patients with de novo AML/ALL in CR1/CR2 who received                       in transplants from 10/10 MUD compared to haploHCT but 
                                                                  T cell-replete haploHCT versus 10/10 MUD or 9/10 MMUD HCT             no difference between 9/10 MMUD and haploHCT.  Acute and
                                                                  between 2007-2013.                                                                                             chronic GvHD were not impacted by the donor type.
Ruggeri et al.83 (2017)                         Retrospective comparative analysis of outcomes of 308 adult               HaploHCT with a PTCy-based prophylaxis produced superior LFS, 
                                                                  patients with AML in CR1/CR2 who underwent T cell-replete                GRFS, and lower incidence of GvHD and NRM compared to
                                                                  haploHCT using PTCy versus ATG-based GvHD prophylaxis                    ATG-based prophylaxis.
                                                                  between 2007-2014.                                                                                             
Versluis et al.57 (2017)                        Retrospective comparative analysis of outcomes of 6,545 adult            Multivariable analysis confirmed no differential impact on OS and
                                                                  patients with poor-risk AML in CR1 receiving an allogeneic                   RFS following MRD, 10/10 MUD, or haplo HCT, and significantly 
                                                                  HCT using MRD versus 10/10 or 9/10 MUD, UCB, T cell-replete             worse OS with 9/10 MUD and UCB grafts. Relapse was decreased
                                                                  haplo-identical donor between 2000-2014.                                                   for 10/10 MUD compared to MRD and haploHCT, and NRM was
                                                                                                                                                                                                 significantly higher for all alternative donors compared to MRD HCT.
Salvatore et al.56 (2017)                      Retrospective comparative analysis of outcomes of 2,654 adult            Int-AML: multivariate analysis showed reduced LFS, OS, GRFS, and
                                                                  patients with int-AML or high-risk AML in CR1 receiving                         higher NRM after haploHCT. High-risk AML: increased grade II-IV
                                                                  T cell-replete haploHCT versus MSD HCT.                                                   aGvHD and lower relapse incidence with haploHCT, and similar NRM,
                                                                                                                                                                                                   LFS, and OS between both donor groups.  
Canaani et al.96 (2017)                       Retrospective comparative analysis of outcomes in 837 adult               Major ABO mismatching was associated with inferior day 100
                                                                  patients with AML who received ABO-matched versus                             engraftment, and bi-directional mismatching had increased risk of
                                                                  ABO-mismatched haploHCT between 2005-2014.                                       grade II-IV aGvHD. Otherwise, NRM, relapse, LFS, OS, and cGvHD
                                                                                                                                                                                                   were similar.
aGvHD: acute graft-versus-host disease; AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; ASCT,: autologous stem cell transplantation; ATG: antithymocyte globulin; BM: bone mar-
row; cGvHD: chronic graft-versus-host-disease; CI: cumulative incidence; CR: complete remission; GRFS: GvHD-free, relapse-free survival; GvHD: graft-versus-host disease; haplo: haploidentical;  HCT:
hematopoietic cell transplantation;  int-AML: intermediate AML; LFS: leukemia-free survival; MA: myeloablative; MMUD: mismatched unrelated donor; MRD: minimal residual disease; MSD: matched
sibling donor; MUD,: matched unrelated donor; NRM: non-relapse mortality; OS: overall survival; PB: peripheral blood; PTCy: post-transplant cyclophosphamide; RFS: relapse-free survival; RI: reduced-
intensity; TRM: transplant-related mortality; UCB: umbilical cord blood; UCBT: umbilical cord blood transplantation.
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following identical RI conditioning regimens for patients
with high-risk leukemia or lymphoma (AML: haplo, n=22;
dUCB, n=29). Results from this trial successfully replicated
those from single-center studies and showed no significant
differences between the two modalities.65 Furthermore,
both cohorts had comparable survival rates to patients
with high-risk hematologic malignancies who underwent
MUD HCT with blood or marrow after RI conditioning.73
An ongoing phase III multicenter randomized trial (clinical-
trials.gov Identifier: 01597778) is attempting to clarify the rel-
ative efficacies of double unrelated cord and haploidentical
related BMT, and the estimated completion date of the trial
is June 2019.  
The Beijing experience
An alternative strategy for prevention of GvHD after T
cell-replete haploidentical donor transplantation has incor-
porated pre-transplant ATG. The Peking University group
in China pioneered an approach that used a combination
of G-CSF-priming of the donor, intensified immunosup-
pression, ATG, and combination of T cell-replete BM plus
peripheral blood as the stem cell source (GIAC protocol)
(Figure 2C).74,75 An early trial in patients with acute
leukemia, including 108 AML patients, suggested encour-
aging GvL effects with universal engraftment, low inci-
dence of relapse following transplantation (13 out of 108
AML patients) and 3-year relapse probabilities of 11.9%
and 20.2% in the standard- and high-risk AML groups,
resulting in DFS rates of 71% and 56%, respectively. While
TRM at D+100 was favorable in both risk groups, the 3-
year TRM in standard-risk and high-risk AML groups was
19.4% and 29.4%. The CI of grade II-IV and grade III-IV
aGvHD were 45.8% and 13.4% at D+100, respectively,
while the 3-year CI of total cGvHD and extensive cGvHD
were 53.9% and 22.6%.75 An updated trial including 756
patients with AL over a time period of 9 years confirmed
their previous findings.76 A subsequent comparative study
in patients with AML who received the GIAC haploHCT
protocol revealed a similar CI of acute and chronic GvHD,
TRM, 5-year relapse and OS rates when compared to
MUD HCT, but a significantly reduced incidence of 5-year
relapse (14.2% vs. 34%, P=0.008) compared to MSD HCT.
A superior GvL effect for high-risk leukemia was also
observed in haploHCT, as 5-year relapse rates were 15.4%,
28.2%, and 49.9% in haplo, MUD (P=0.07), and MSD
HCT, respectively (P=0.002).77 Results from Wang et al.78
also suggested a superior GvL effect by haploHCT com-
pared to a matched sibling HCT in patients with high-risk
AL (50 AML out of 117), whereas other studies indicated
no significant difference.79,80 In three of the four studies,
grade II-IV aGvHD was significantly more frequent after
haploHCT compared to MSD HCT. In the only prospec-
tive study comparing post-transplantation outcomes in 450
patients with intermediate- or high-risk AML in CR1 who
received a haplo or MSD HCT, Wang et al.81 demonstrated
a similar CI of relapse (15% vs. 15%, P=0.98), 3-year DFS
(74% vs. 78%, P=0.34), NRM (13% vs. 8%, P=0.13), and
OS (79% vs. 82%, P=0.36). The CI of 100-day aGvHD and
1-year cGvHD, including severe cGvHD, was significantly
higher in the haploHCT group. Owing to the lack of ran-
domization, this comparative study suggests haploidenti-
cal HCT as a valid alternative option for this patient popu-
lation for whom no matched sibling donor is available. 
Due to the reported high leukemia-free survival rates
associated with the Beijing strategy, the ALWP of the
EBMT performed a retrospective one-to-one matched pair
comparative study of outcomes following GIAC-based
haploidentical HCT and myeloablative (non-TBI based)
10/10 MUD HCT in patients with de novo intermediate-
risk (based on cytogenetics) AML in CR1.82 Subjects were
matched in age, time to transplant, and number of induc-
tion courses to reach CR1. Similar outcomes were
observed between haploHCT and MUD HCT in terms of
5-year LFS (73.5% vs. 60.3%, P=0.15), OS (78.2% vs.
63.6%, P=0.15), relapse (12.7% vs. 24%, P=0.08), NRM
(13.8% vs. 15.7%, P=0.96), grade III-IV aGvHD (9.2% vs.
9.4%, P=1), and cGvHD (42.5% vs. 34.9%, P=0.39). Based
on this analysis, the authors concluded that the Beijing pro-
tocol is a feasible alternative to allogeneic transplantation
with a 10/10 MUD.  
Following several publications showing very low inci-
dences of GvHD after ATG-based intensive immunosup-
pression established in the GIAC haploHCT protocol,
Ruggeri et al.83 compared this GvHD prophylaxis regimen
to the PTCy platform in the setting of unmanipulated
haploHCT for patients with various-risk AML in CR1 or
CR2. A total of 308 patients were studied (PTCy, n=193;
ATG, n=115), and both groups were well matched in
regards to recipient and donor age, AML disease risk, dis-
ease status at transplant, and conditioning intensity.
Notably, a  BM stem cell source was used more frequently
in the PTCy group (60.1% vs. 39.9%, P=0.01), and that
cohort also had shorter follow up (18 vs. 36 months,
P<0.001). At day 100, similar outcomes in grade II-V
aGvHD were observed between patients receiving PTCy
versus ATG (31% vs. 21%, P=0.07), however, grade III-IV
aGvHD was significantly lower in the PTCy group (4.7%
vs. 12.5%, P=0.01). The incidence of 2-year cGvHD did not
differ between the two groups (33.7% vs. 28.3%, P=0.33).
Multivariate analysis of NRM, LFS, OS, and GRFS also sig-
nificantly favored the PTCy regimen.
Although different haploHCT methods have not been
prospectively compared in a randomized fashion, the
available cumulative evidence demonstrates the feasibility
of haploidentical transplantation and the benefit of having
a readily accessible donor, regardless of the platform used.
Ongoing research in T cell-replete haploidentical
transplantation 
Since the demonstration of the safety and efficacy of
NMA haploHCT with PTCy, there has been increasing
research interest in optimizing clinical outcomes for differ-
ent patient populations through modifications of the origi-
nal platform. For example, some groups have explored
optimizing the anti-leukemia effects of haploHCT, partic-
ularly in high-risk or advanced AML, by intensifying the
conditioning regimen or substituting BM with PBSC as the
stem cell graft source, due to the concern of high relapse
rates associated with NMA haploHCT and PTCy. In the
former setting, several single-center non-comparative stud-
ies have reported a low risk of acute and chronic GvHD
and encouraging rates of TRM and OS with myeloablative
conditioning.84-87 These observations were recently validat-
ed by the first large retrospective comparative analysis per-
formed by the ALWP-EBMT showing similar OS, LFS,
NRM, and cGvHD between MA and RI conditioning regi-
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mens in T cell-replete haploHCT, in particular for patients
with AML in CR1.88 Multivariable analyses revealed a
trend towards higher relapse incidence, with RI versus MA
conditioning (HR 1.34, P=0.09), and when taken collective-
ly the data supported the use of either high or low intensi-
ty conditioning haploHCT with PTCy in the first-line
treatment of high-risk AML.88 In this study, there was an
increased risk of grade II-IV aGvHD and cGvHD independ-
ent of the conditioning regimen intensity and of the use of
PTCy with the use of a PBSC graft compared to BM, but
no difference was seen with regard to the incidence of
NRM and other survival outcomes.88 Ruggeri et al.89 also
described the use of PBSC as the sole factor associated
with an increased risk of grade II-IV aGvHD (HR 2.2, 95%
CI 1.27-3.9, P=0.005) in patients with AL, the majority of
whom were transplanted with a MA regimen for AML in
CR1. Otherwise, the type of stem cell graft (PBSC vs. BM)
proved to have no significant difference on grade III-IV
aGvHD, cGvHD, relapse, or survival. In line with the
attempts to exploit a PBSC source, Peccatori et al. devel-
oped a calcineurin inhibitor-free GvHD prophylaxis based
on rapamycin, mycophenolate mofetil and ATG, with the
aim of promoting a fast post-transplant immune recovery
with a preferential accumulation of regulatory T cells.90
Recently, this sirolimus platform has been modified with
the substitution of ATG by PTCy, which showed a signif-
icant reduction in cGvHD.91 In the NMA haploHCT set-
ting, both Castagna et al.92 and O’ Donnell et al.93 reported
comparable outcomes in acute and chronic GvHD, engraft-
ment rates, NRM, and OS after haplo-BM or haplo-PBSC
transplantation; however, the incidence of relapse at 1 to 3
years was significantly lower after haplo-PBSC transplant
compared with haplo-BM transplants in the latter study.
Other groups have also demonstrated the feasibility of
NMA haploHCT with either PBSC or BM stem cells in
older adults.94,95 The significance of ABO incompatibility on
outcomes after haploHCT for AML have recently been
published by the ALWP-EBMT, and preliminarily demon-
strate a significantly increased risk of grade II-IV aGvHD
with bi-directional ABO mismatching and a lower OS rate
in patients with major ABO mismatching transplanted
with BM grafts.96 Lastly, the impact of haploHCT for spe-
cific high-risk AML cytogenetic and molecular risk groups
as well as the role of post-transplant cellular therapies are
of interest. 
The significance of pre-transplant MRD as a poor prog-
nostic and predictive factor of outcomes after allogeneic
HCT in AML has been reported.3,97-99 For example, the
Seattle group published inferior 3-year OS and relapse out-
comes among AML patients receiving a myeloablative
matched donor HCT with pre-transplant MRD-positive
(morphologic remission) compared to MRD-negative
(morphologic remission), and further demonstrated com-
parable outcomes to patients with active disease at the
time of HCT.3 Several other groups have studied the signif-
icance of pre-transplant MRD on a more granular level and
demonstrated that the level of pre-transplant MRD may
differentially impact post-transplantation outcomes100,101
The significance of pre-transplant MRD has also been
described in the setting of haploHCT.102,103 Wang et al.102 ret-
rospectively evaluated outcomes of 255 patients with AML
in CR1 or CR2. Multivariate analysis indicated failure of
CR after 2 courses of induction therapy as the strongest
independent prognostic factor for relapse and LFS. In sub-
group analysis, positive pre-transplant MRD as compared
to negative MRD also resulted in worse LFS at 3 years
(76% vs. 52%, P=0.041) and CI of relapse at 2 years (10%
vs. 35%, P=0.002). These results must be interpreted cau-
tiously due to the limited patient sample (negative MRD,
n=110; positive MRD, n=20). Conversely, other groups
have reported no significant influence of MRD status (pos-
itive vs. negative) prior to haploHCT on PFS104 or relapse103
for patients with AML in CR1/CR2, and further hypothe-
size that while detectable MRD before HCT is a strong
unfavorable prognostic factor, its adverse impact may be
overcome by the potentially stronger GvL effects of unma-
nipulated haploHCT.103
Perspectives  
Over the last two decades, the international BMT com-
munity have witnessed incredible advances in HLA-typ-
Table 3. Comparative studies of haploidentical HCT versus umbilical cord blood transplantation.
Author                 Disease,        Condition         Graft              Donor           Engraft      aGvHD          aGvHD         cGvHD           OS             DFS             Relapse        NRM 
                           no of pts.                              Source              Type                (%)       II-IV (yr)       III-IV (yr)          (yr)             (yr)              (yr)                 (yr)             (yr)
                            (AML, n)      Intensity (%)        (n)        (no. of patients)          
Rocha et al.69          AML, 220                 NR           NR (haplo)      Haplo (154)             NR         5 =/- 5%              NR                  NR                 NR           24±4% (2)       18±3% (2)      58±4%
                                                                                                                  UCB (66)                              23 +/- 5%                                                                                30±6%              24±5%         46±2%
                                                                                                                                                                   <0.0001                                                                               (P=0.39)          (P=0.44)     (P=0.23)
Brunstein et al.65^   All, 100              RI (100)         BM (50)          Haplo (50)               94       32% (d100)     0% (d100)       13% (1)        62% (1)         48% (1)            45% (1)         7% (1)
                                 (AML, 51)                                                              UCB (50)                96              40%                 21%                25%               54%                46%                    31%               24%
Ruggeri et al.71       AML, 918          MA (54%)      BM (171)        Haplo (360)              91          27% (*)          11% (*)         29% (*)        38% (*)         32% (2)            41% (*)       27% (*)
                                                              RI (46%)         PB (78)           UCB (558)               84              31%                 12%                24%               42%                38%                    32%               30%
                                                                                      Both (14)                                     (P=0.003)  (P=0.10)        (P=0.41)       (P=0.19)     (P=0.269)    (P=0.102)       (P=0.008)α   (P=0.356)
El-Cheikh et al.72     All, 150              RI (100)        BM (NR)         Haplo (69)               94          34% (*)           5% (*)           6% (*)         69% (2)         65% (2)            18% (*)       18% (2)
                                 (AML, 40)                                   PB (NR)           UCB (81)                90              50%                 33%                12%               45%                36%                    38%               23%
                                                                                                                                                                  (P=0.08)      (P<0.0001)    (P=0.001)     (P=0.10)       (P=0.01)          (P=0.03)     (P=0.49)
^The data are from 2 separate but parallel multicenter phase 2 trials with identical objectives, eligibility, and clinical endpoints. The clinical outcomes should not be compared directly.  * Year not
reported. αMultivariate analysis of relapse was not statistically different between the haplo and UCB groups (HR 0.95, P=0.76). aGvHD: acute graft-versus-host disease; AML: acute myeloid leukemia;
ALL: acute lymphocytic leukemia; BM: bone marrow; cGvHD, chronic graft-versus-host-disease; DFS: disease-free survival; haplo: haploidentical; MA: myeloablative; NRM: non-relapse mortality; NR:
not reported; OS: overall survival; PB: peripheral blood; RI: reduced-intensity; UCB: umbilical cord blood; yr, year.
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ing and alternative donor transplantation strategies, such
that in the present day nearly all transplant-eligible
patients with AML will have an available donor.
Unmanipulated haploidentical related transplantation
with post-transplant cyclophosphamide has emerged as a
potentially powerful strategy for the cure of AML and is
the dominant haploHCT platform in Europe.105 Other sig-
nificant advantages of haploHCT with PTCy include its
associated low non-relapse mortality and GvHD, ease of
donor accessibility often leading to minimal length of time
to transplantation, and low acquisition costs. The cost-
effectiveness associated with haploHCT with PTCy may
have the most appeal in developing countries, where eco-
nomic resources are more limited.105 Unmanipulated hap-
loidentical transplantation with post-transplantation
immunosuppression also shows promise in decreasing
post-transplant infections and death due to infections,
however, further data on immune reconstitution, infec-
tions and their related complications (i.e., hemorrhagic
cystitis) among different haploHCT strategies are war-
ranted.106 The incidence of post-transplant cardiomyopa-
thy secondary to GvHD prophylaxis with high-dose
PTCy appears non-significant in the absence of severe
infection,107 however, further research evaluating predic-
tive factors for cardiomyopathy following PTCy based
HCT are necessary. While there has been questioning of
donor-derived malignancies (DDM) associated with
PTCy, a recent retrospective study by the Hopkins group
showed an extremely low proportion of patients with a
DDM (4 out of 789) over a 10-year period, suggesting that
PTCy does not appear to increase the risk of DDM.108
However, the authors acknowledge the short follow-up
period of their study and report the need for continued
close monitoring of DDMs over a longer follow-up time.  
Another key issue arising in the setting of unmanipulat-
ed haploHCT is the selection of the “best” donor, as some
patients will have multiple haploidentical donor candi-
dates and donor selection may significantly impact
GvHD, relapse, TRM, and survival outcomes. Owing to
improved approaches of unmanipulated haploHCT with
PTCy or ATG-based GvHD prophylaxis, the effects of
HLA disparity have vanished, nonetheless, other donor-
related variables should be considered. These include the
selection of donors for whom there are no recipient
donor-specific antibodies (DSA); alternatively, measures
to remove DSA should be undertaken in the patient; the
selection of a younger, male donor over an older, female
donor due to the potential for superior survival, decreased
risk of grade II-IV aGvHD and age-related clonal
hematopoiesis leading to subsequent malignancies; and
the selection of an ABO compatible donor, followed by a
minor ABO mismatched and then a major ABO mis-
matched donor. Other factors to consider include donor
and recipient cytomegalovirus (CMV) serostatus, NK cell
alloreactivity and KIR haplotype matching, and non-inher-
ited maternal HLA antigens (NIMA) mismatching.109
However, more research is needed as the significance of
each of these factors may change depending on the
haploHCT protocol or platform used, and indeed, may
vanish, due to the emergence of new variables as
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Figure 3. Recommended donor choice algorithm for adults with intermediate or high-risk AML with an indication for allogeneic HCT. AML: acute myeloid leukemia;
BM: bone marrow; CR: complete remission; alloHCT: allogeneic hematopoietic cell transplantation; haploHCT: haploidentical hematopoietic cell transplantation;
MMUD: mismatched unrelated donor; MRD: matched related donor; MUD: matched unrelated donor; PB: peripheral blood; UCB: umbilical cord blood; UCBT: umbilical
cord blood transplantation. RI: reduced-intensity; MA: myeloablative.
haploHCT becomes increasingly utilized.
In conclusion, the growing body of literature has consis-
tently demonstrated comparable outcomes of haploidenti-
cal donor HCT as compared to an UCB, matched sibling
and unrelated donor transplantation for patients with
AML. However, the available studies are nonrandomized,
underpowered, and lack long-term follow-up data.
Accordingly, the ALWP-EBMT endorses haploidentical
transplantation as a valid post-remission therapy for high-
risk AML in the absence of a matched donor or in the case
of the need for an urgent transplant procedure (Figure 3).
Further prospective studies randomizing haploHCT to
UCBT (in the USA) or to MUD or MMUD HCT (in
Europe) are ongoing, and will help to establish its position
in the hierarchy of alternative donors.
Position statement from the ALWP- EBMT 
• Haploidentical donor transplantation is a valid option
for patients with AML lacking a matched sibling or unre-
lated donor.
• In certain clinical situations, especially in the case of a
need for an urgent transplant procedure and lack of a
MDS, a readily available haploidentical donor may be
considered over initiating an unrelated donor search. 
• The evidence for the superiority of haploidentical vs.
MMUD vs. UCBT is insufficient, but there is the potential
for a cost benefit with regard to haploHCT.
• There is insufficient evidence for the superiority of
one haploidentical HCT platform over another. Economic
factors, together with individual center experience, may
be decisive.
C.J. Lee et al.
1820 haematologica | 2017; 102(11)
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